OSTEOPOROSIS IN CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE
https://doi.org/10.14412/1995-4484-2013-1198
Abstract
Objective: to study the incidence of osteoporosis (OP) in patients with calcium pyrophosphate crystal deposition disease (CPCDD). Subjects and methods. Eighty patients with CPCDD were examined. Bone mineral density (BMD) of the forearm, lumbar spine, and femoral neck was determined by dual-energy X-ray absorptiometry. Laboratory diagnosis involved determination of the blood levels of C-reactive protein, parathyroid hormone, calcium, magnesium, and phosphorus and the daily urinary excretion of calcium and phosphates. Results. The patients with OP were significantly older than those with normal BMD and osteopenia. Forearm bones were the most common isolated location of OP and osteopenia. Injuries in the history, traumatic fractures, and the intake of diuretics were somewhat more common in the patients diagnosed with OP. The incidence of hyperparathyroidism did not differ significantly in the groups.
About the Authors
S A Vladimirov
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт ревматологии» РАМН, Москва
F M Kudayeva
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт ревматологии» РАМН, Москва
Viktoria Geogiyevna Barskova
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт ревматологии» РАМН, Москва
References
1. <div><p>Institute for Clinical Systems Improvement (ICSI) Health Care Guideline: Diagnosis and Treatment of Osteoporosis. 3rd ed. July 2004.</p><p>Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации Российской ассоциации по остеопорозу. М.: ГЭОТАР-медиа, 2005;171 с.</p><p>Дыдыкина И.С. Роль витамина D в лечении остеопороза. Совр ревматол 2008;1:12-6.</p><p>Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблема остеопороза в ревматологии. М.: СТИН, 1997;429 с.</p><p>Насонов Е.Л. Остеопороз при ревматических заболеваниях. В кн.: Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ, 2003;346—59.</p><p>Барскова В.Г., Ильина А.Е., Семенова Л.А. и др. Пирофосфатная артропатия ревматологический синдром «айсберга»: время для переоценки значения в патологии суставов. Совр ревматол 2010;2:5-10.</p><p>Richette P., Bardin T., Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009;48(7):711-5.</p><p>Zhang W., Doherty M., Bardin T. et al. EULAR evidence based recommendations for calcium pyrophosphate deposition (CPPD). Part II: management. Ann Rheum Dis 2010;69(Suppl 3):120.</p><p>Doherty M., Dieppe P. Crystal deposition disease in the elderly. [Review] [99 refs]. Clin Rheum Dis 1986;12:97-116.</p><p>Ryan L.M., McCarty D.J. Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. In: Koopman W., Baltimore M., eds. Arthritis and Allied Conditions: A textbook of Rheumatology. Williams and Wilkins, 1997;2103-26.</p><p>McCarty D.J Calcium pyrophosphate dihydrate crystal deposition disease. Arthr Rheum 1976;19(Suppl 3):275—85.</p><p>Brown J.P., Josse R.G. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(Suppl 10):S1-S34.</p><p>Schumacher H.R., Chen X.L. Gout and other crystal-associated arthropathies. In: Wiener C., Fauci A.S., Braunwald E. et al. (eds). Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill, 2008;1-5.</p><p>The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine Pract 2005;11(1):49-54.</p><p>Tromp A.M., Ooms M.E., Popp-Snijders C. et al. Predictors of fractures in elderly women. Osteoporos Int 2000;11:134-40.</p><p>Heidrich F.E., Stergachis A., Gross K.M. Diuretic drug use and the risk for hip fracture. Ann Intern Med 1991;115:1-6.</p><p>Rejnmark L., Vestergaad P., Heickendorff L. et al. Effects of longterm treatment with loop diuretics on bone mineral density, cal-citropic hormones and bone turnover. J Intern Med 2005;257(2):176-84.</p><p>Bolland M.J., Ames R.W., Horne A.M. et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 2007;18(4):479-86.</p><p>University of Michigan Health System. Guidelines for Clinical Care: Osteoporosis: Prevention and Treatment. July 2005.</p></div><br />
Review
For citations:
Vladimirov S.A., Kudayeva F.M., Barskova V.G. OSTEOPOROSIS IN CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE. Rheumatology Science and Practice. 2013;51(1):34-37. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1198
Views:
860
Email this article 